Joseph P Colgan
Overview
Explore the profile of Joseph P Colgan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
947
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Indrabhinduwat M, Calle M, Colgan J, Villarraga H
Echo Res Pract
. 2018 Jul;
5(3):K53-K58.
PMID: 30006443
Learning Points: Lymphoma can be found as a primary tumor in cardiac tissue, but secondary cardiac lymphoma is far more common.Appropriate investigation, histopathology, immunophenotype, staging and risk assessment are required...
2.
Stitt D, Boes C, Flanagan E, Howard M, Colgan J
Mult Scler Relat Disord
. 2017 Dec;
19:115-117.
PMID: 29190574
The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There...
3.
Epperla N, Pham A, Burnette B, Wiseman G, Habermann T, Macon W, et al.
Br J Haematol
. 2017 May;
178(3):427-433.
PMID: 28466487
Histological transformation (HT) of follicular lymphoma (FL) to an aggressive lymphoma after chemotherapy remains a key issue. The incidence of HT after radioimmunotherapy (RIT) is unknown. This single institution study...
4.
Bennani N, LaPlant B, Ansell S, Habermann T, Inwards D, Micallef I, et al.
Am J Hematol
. 2017 Feb;
92(5):448-453.
PMID: 28211162
Relapsed indolent lymphoma often becomes refractory to standard chemoimmunotherapy and requires new therapeutic strategies. Targeting the PI3K/mTOR pathway in several types of lymphoma has shown preclinical and clinical efficacy providing...
5.
Kapoor P, Ansell S, Fonseca R, Chanan-Khan A, Kyle R, Kumar S, et al.
JAMA Oncol
. 2017 Jan;
3(9):1257-1265.
PMID: 28056114
Importance: Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array of therapies, the management strategies have become increasingly...
6.
Johnston P, Laplant B, McPhail E, Habermann T, Inwards D, Micallef I, et al.
Lancet Haematol
. 2016 Jul;
3(7):e309-16.
PMID: 27374464
Background: The PI3K-mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targeted with the mTOR complex 1 (mTORC1) inhibitor everolimus. Everolimus has activity in relapsed DLBCL....
7.
Kenderian S, Habermann T, Macon W, Ristow K, Ansell S, Colgan J, et al.
Blood
. 2016 Feb;
127(16):1960-6.
PMID: 26837698
A number of reports have shown a propensity of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL). Long-term data on the incidence and outcomes of...
8.
Witzig T, Reeder C, Han J, Laplant B, Stenson M, Tun H, et al.
Blood
. 2015 Apr;
126(3):328-35.
PMID: 25921059
Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity...
9.
Briski R, Feldman A, Bailey N, Lim M, Ristow K, Habermann T, et al.
Leuk Lymphoma
. 2014 Sep;
56(6):1665-70.
PMID: 25248884
The natural history of limited-stage peripheral T-cell lymphoma (PTCL) remains poorly defined. Therefore, we examined outcomes in patients with the most common PTCL subtypes (PTCL, not otherwise specified [PTCL, NOS],...
10.
Witzig T, Maurer M, Habermann T, Link B, Micallef I, Nowakowski G, et al.
Am J Hematol
. 2014 Sep;
89(12):1116-20.
PMID: 25228125
The serum immunoglobulin free light chain (FLC) assay quantitates free kappa (κ) and lambda (λ) light chains. FLC elevations in patients with diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL),...